Which has better valuation and earnings, MMED or AORT?

Artivion has lower revenue, but higher earnings than MiniMed Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.37 N/A N/A N/A Artivion $458.69M 2.29 $9.77M $0.24 90.35

Which has better earnings & valuation, WRBY or AORT?

Artivion has lower revenue, but higher earnings than Warby Parker. Artivion is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $890.57M 3.26 $1.64M $0.02 1,355.90 Artivion $458.69M 2.29 $9.77M $0.24 90.35

Is WRBY or AORT more profitable?

Artivion has a net margin of 2.55% compared to Warby Parker's net margin of 0.15%. Artivion's return on equity of 7.15% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% Artivion 2.55% 7.15% 3.63%

Which has better valuation and earnings, AORT or TMDX?

TransMedics Group has higher revenue and earnings than Artivion. TransMedics Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $458.69M 2.29 $9.77M $0.24 90.35 TransMedics Group $605.49M 4.43 $190.29M $4.40 17.63

Which has preferable valuation & earnings, ESTA or AORT?

Artivion has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 12.39 -$51.06M -$1.49 N/A Artivion $458.69M 2.29 $9.77M $0.24 90.35

Artivion (AORT) Competitors

$21.68 +1.00 (+4.85%)

As of 12:02 PM Eastern

Compare

AORT vs. MMED, IRTC, WRBY, TMDX, and ESTA

Should you buy Artivion stock or one of its competitors? MarketBeat compares Artivion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artivion include MiniMed Group (MMED), iRhythm Technologies (IRTC), Warby Parker (WRBY), TransMedics Group (TMDX), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

How does Artivion compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Artivion (NYSE:AORT) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

In the previous week, MiniMed Group had 1 more articles in the media than Artivion. MarketBeat recorded 1 mentions for MiniMed Group and 0 mentions for Artivion. MiniMed Group's average media sentiment score of 0.00 equaled Artivion'saverage media sentiment score.

Company	Overall Sentiment
MiniMed Group	Neutral
Artivion	Neutral

MiniMed Group currently has a consensus price target of $21.33, suggesting a potential upside of 46.17%. Artivion has a consensus price target of $44.17, suggesting a potential upside of 103.68%. Given Artivion's stronger consensus rating and higher possible upside, analysts clearly believe Artivion is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Artivion has a net margin of 2.55% compared to MiniMed Group's net margin of 0.00%. Artivion's return on equity of 7.15% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Artivion	2.55%	7.15%	3.63%

19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 2.2% of MiniMed Group shares are held by insiders. Comparatively, 6.3% of Artivion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Artivion has lower revenue, but higher earnings than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.37	N/A	N/A	N/A
Artivion	$458.69M	2.29	$9.77M	$0.24	90.35

Summary

Artivion beats MiniMed Group on 8 of the 11 factors compared between the two stocks.

How does Artivion compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Artivion (NYSE:AORT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, iRhythm Technologies had 3 more articles in the media than Artivion. MarketBeat recorded 3 mentions for iRhythm Technologies and 0 mentions for Artivion. iRhythm Technologies' average media sentiment score of 0.58 beat Artivion's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
iRhythm Technologies	Positive
Artivion	Neutral

86.4% of Artivion shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Artivion has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.88	-$44.55M	-$0.86	N/A
Artivion	$458.69M	2.29	$9.77M	$0.24	90.35

Artivion has a net margin of 2.55% compared to iRhythm Technologies' net margin of -3.53%. Artivion's return on equity of 7.15% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Artivion	2.55%	7.15%	3.63%

iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Artivion has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

iRhythm Technologies currently has a consensus target price of $187.38, indicating a potential upside of 68.75%. Artivion has a consensus target price of $44.17, indicating a potential upside of 103.68%. Given Artivion's higher probable upside, analysts plainly believe Artivion is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Artivion beats iRhythm Technologies on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to Warby Parker?

Warby Parker (NYSE:WRBY) and Artivion (NYSE:AORT) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 16.8% of Warby Parker shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Warby Parker currently has a consensus price target of $29.50, indicating a potential upside of 8.78%. Artivion has a consensus price target of $44.17, indicating a potential upside of 103.68%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Artivion has lower revenue, but higher earnings than Warby Parker. Artivion is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$890.57M	3.26	$1.64M	$0.02	1,355.90
Artivion	$458.69M	2.29	$9.77M	$0.24	90.35

In the previous week, Warby Parker had 10 more articles in the media than Artivion. MarketBeat recorded 10 mentions for Warby Parker and 0 mentions for Artivion. Warby Parker's average media sentiment score of 0.90 beat Artivion's score of 0.00 indicating that Warby Parker is being referred to more favorably in the media.

Company	Overall Sentiment
Warby Parker	Positive
Artivion	Neutral

Artivion has a net margin of 2.55% compared to Warby Parker's net margin of 0.15%. Artivion's return on equity of 7.15% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
Artivion	2.55%	7.15%	3.63%

Warby Parker has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Artivion has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Summary

Warby Parker beats Artivion on 9 of the 16 factors compared between the two stocks.

How does Artivion compare to TransMedics Group?

Artivion (NYSE:AORT) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, TransMedics Group had 5 more articles in the media than Artivion. MarketBeat recorded 5 mentions for TransMedics Group and 0 mentions for Artivion. TransMedics Group's average media sentiment score of 0.74 beat Artivion's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Artivion	Neutral
TransMedics Group	Positive

86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artivion currently has a consensus price target of $44.17, suggesting a potential upside of 103.68%. TransMedics Group has a consensus price target of $134.50, suggesting a potential upside of 73.36%. Given Artivion's stronger consensus rating and higher possible upside, analysts clearly believe Artivion is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has a net margin of 27.04% compared to Artivion's net margin of 2.55%. TransMedics Group's return on equity of 22.38% beat Artivion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	2.55%	7.15%	3.63%
TransMedics Group	27.04%	22.38%	8.46%

Artivion has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than Artivion. TransMedics Group is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$458.69M	2.29	$9.77M	$0.24	90.35
TransMedics Group	$605.49M	4.43	$190.29M	$4.40	17.63

Summary

TransMedics Group beats Artivion on 12 of the 16 factors compared between the two stocks.

How does Artivion compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Artivion (NYSE:AORT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Establishment Labs currently has a consensus price target of $87.14, suggesting a potential downside of 1.94%. Artivion has a consensus price target of $44.17, suggesting a potential upside of 103.68%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Establishment Labs had 4 more articles in the media than Artivion. MarketBeat recorded 4 mentions for Establishment Labs and 0 mentions for Artivion. Establishment Labs' average media sentiment score of 1.31 beat Artivion's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Establishment Labs	Positive
Artivion	Neutral

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Artivion has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Artivion has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.39	-$51.06M	-$1.49	N/A
Artivion	$458.69M	2.29	$9.77M	$0.24	90.35

Artivion has a net margin of 2.55% compared to Establishment Labs' net margin of -19.05%. Artivion's return on equity of 7.15% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Artivion	2.55%	7.15%	3.63%

Summary

Artivion beats Establishment Labs on 11 of the 15 factors compared between the two stocks.

Get Artivion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AORT vs. The Competition

Export

Metric	Artivion	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.05B	$7.19B	$6.55B	$23.22B
Dividend Yield	N/A	1.27%	2.69%	4.06%
P/E Ratio	90.36	50.13	25.18	31.25
Price / Sales	2.29	89.39	554.67	107.90
Price / Cash	18.27	24.78	44.82	24.45
Price / Book	2.29	7.42	10.82	4.70
Net Income	$9.77M	$159.20M	$3.56B	$1.07B
7 Day Performance	1.95%	1.20%	1.98%	0.67%
1 Month Performance	-3.40%	0.67%	1.43%	0.78%
1 Year Performance	-30.29%	7.43%	31.13%	23.29%

Artivion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AORT Artivion	4.0392 of 5 stars	$21.68 +4.9%	$44.17 +103.7%	-32.9%	$1.05B	$458.69M	90.36	1,800
MMED MiniMed Group	3.876 of 5 stars	$14.22 -3.7%	$21.33 +50.0%	N/A	$3.99B	$2.99B	N/A	8,000
IRTC iRhythm Technologies	4.0544 of 5 stars	$104.69 +0.0%	$187.38 +79.0%	-27.0%	$3.44B	$787.85M	N/A	2,400	Analyst Forecast
WRBY Warby Parker	3.7369 of 5 stars	$26.95 +3.8%	$29.50 +9.4%	+16.8%	$2.78B	$871.91M	1,348.32	4,036
TMDX TransMedics Group	4.6449 of 5 stars	$75.51 -4.2%	$134.50 +78.1%	-42.1%	$2.72B	$605.49M	17.16	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AORT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artivion (AORT) Competitors

AORT vs. MMED, IRTC, WRBY, TMDX, and ESTA

How does Artivion compare to MiniMed Group?

Summary

How does Artivion compare to iRhythm Technologies?

Summary

How does Artivion compare to Warby Parker?

Summary

How does Artivion compare to TransMedics Group?

Summary

How does Artivion compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artivion (AORT) Competitors

AORT vs. MMED, IRTC, WRBY, TMDX, and ESTA

How does Artivion compare to MiniMed Group?

Does the media prefer MMED or AORT?

Do analysts prefer MMED or AORT?

Is MMED or AORT more profitable?

Do institutionals & insiders hold more shares of MMED or AORT?

Which has better valuation and earnings, MMED or AORT?

Summary

How does Artivion compare to iRhythm Technologies?

Does the media favor IRTC or AORT?

Do insiders and institutionals believe in IRTC or AORT?

Which has higher valuation and earnings, IRTC or AORT?

Is IRTC or AORT more profitable?

Which has more volatility and risk, IRTC or AORT?

Do analysts rate IRTC or AORT?

Summary

How does Artivion compare to Warby Parker?

Do insiders & institutionals believe in WRBY or AORT?

Do analysts recommend WRBY or AORT?

Which has better earnings & valuation, WRBY or AORT?

Does the media prefer WRBY or AORT?

Is WRBY or AORT more profitable?

Which has more volatility & risk, WRBY or AORT?

Summary

How does Artivion compare to TransMedics Group?

Does the media favor AORT or TMDX?

Do insiders & institutionals hold more shares of AORT or TMDX?

Do analysts rate AORT or TMDX?

Is AORT or TMDX more profitable?

Which has more risk and volatility, AORT or TMDX?

Which has better valuation and earnings, AORT or TMDX?

Summary

How does Artivion compare to Establishment Labs?

Do analysts rate ESTA or AORT?

Does the media refer more to ESTA or AORT?

Do insiders & institutionals hold more shares of ESTA or AORT?

Which has more volatility & risk, ESTA or AORT?

Which has preferable valuation & earnings, ESTA or AORT?

Is ESTA or AORT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AORT vs. The Competition

Artivion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools